Navigation Links
Janssen, the Pharmaceutical Companies of Johnson & Johnson, Announces First-of-its-Kind Drug Donation Program for HIV Treatment-Experienced Children
Date:12/9/2013

CAPE TOWN, South Africa, Dec. 9, 2013 /PRNewswire/ -- Janssen, the pharmaceutical companies of Johnson & Johnson, today announced a first-of-its-kind pediatric HIV treatment donation program to improve access to the company's approved HIV medicines for children and adolescents failing HIV treatment in sub-Saharan Africa. At a symposium entitled When Children Need HIV Treatment Beyond First-Line: How Can We All Respond? at the 17th International Conference on AIDS and STIs in Africa (ICASA), Ministries of Health (MOHs) in sub-Saharan Africa were invited to submit a formal Expression of Interest to participate in the charitable pediatric HIV treatment donation program.

Through this program, Janssen will donate its HIV medicines PREZISTA® (darunavir) and INTELENCE® (etravirine), including child-friendly formulations, free of charge to eligible countries with the clinical capacity and willingness to address second- and third-line pediatric HIV treatment. Each child enrolled will receive Janssen's donated HIV medicines as needed until they turn 19 at which point they will be transitioned into the adult national HIV program or other designated by the national HIV program for continued treatment.

The donation program is intended to be a first step in a broader collaborative effort to build awareness, incite action, and advance learning around second- and third-line pediatric HIV treatment in sub-Saharan Africa. Janssen is working with the Elizabeth Glaser Pediatric AIDS Foundation, the Partnership for Supply Chain Management (PFSCM), and MAP International to fully maximize the impact and reach of this initiative.

"The donation program is part of our longstanding commitment to help people living with HIV and enhance access to our medicines for those in need. Only a third of the 3 million children living with HIV are receiving medicines today, and of those children receiving treatment, a small but growing number are experiencing HIV treatment failures and are in need of new treatment options," said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Janssen. "We hope this innovative donation program is the first step in sparking further collaborative action across sub-Saharan Africa for children who are experiencing HIV treatment failure. Our vision is that these children receive the HIV treatment and care they need to stay healthy and grow to become healthy, productive young adults."

Treatment of pediatric HIV remains significantly neglected in sub-Saharan Africa. Responding to the challenge of HIV treatment-experienced children requires a comprehensive effort to help guide countries in the provision of necessary and appropriate care for this neglected population.  This includes improving understanding of the problem, expanding national treatment guidelines beyond first-line, increasing healthcare capacity for pediatric HIV treatment and monitoring, and ensuring that availability of co-administered HIV medicines remains a priority.

The submission period for the Expression of Interest by country MOHs to participate in the drug donation initiative will run from January 15, 2014 until February 14, 2014. An independent, third-party review committee of international experts in pediatric HIV will review all applications to determine country eligibility to receive the donation.  Country approvals will be announced in March 2014. Countries interested in more information or submitting an Expression of Interest should visit: www.pedaids.org/treatmentdonation.

About Janssen, the Pharmaceutical Companies of Johnson & Johnson
At Janssen, we are dedicated to addressing and solving the most important unmet medical needs of our time, including in oncology (e.g., multiple myeloma and prostate cancer), immunology (e.g., rheumatoid arthritis, IBD and psoriasis), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).

Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. To learn more, visit www.janssen.com.

About Johnson & Johnson
Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,700 employees at more than 275 Johnson & Johnson operating companies work with partners in healthcare to touch the lives of over a billion people every day throughout the world.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of any of the Janssen Pharmaceutical Companies or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; impact of business combinations; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)


'/>"/>
SOURCE Janssen
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
2. UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Against ARIAD Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ARIA
3. Auxilium Pharmaceuticals, Inc. To Present At The Oppenheimer Conference
4. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
5. Savara Pharmaceuticals Appoints Two New Members to Its Board of Directors
6. Auxilium Pharmaceuticals, Inc. Announces Court Grants Upsher-Smith Laboratories Motion For Summary Judgment
7. Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas
8. Corporate News, Acquisitions: Herbalife Ltd, 3D Systems Corporation, Federal National Mortgage Association, Galena Biopharma Inc, Oncomed Pharmaceuticals
9. RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
10. Global Oil, Gas and Pharmaceutical Business Confidence Market Research Report q4 2013 Available on Researchmoz.us
11. Governor OMalley Announces $200 Million Investment In Maryland By Top Brazilian Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- Stock-Callers.com today presents the following Generic Drugs ... ), Sophiris Bio Inc. (NASDAQ: SPHS ), Momenta ... Inc. (NASDAQ: AGRX ). These companies are part ... trade on Friday, January 20 th , 2017, with the ... health care companies in the S&P 500 also were sinking ...
(Date:1/23/2017)... , 23. Januar 2017  ResMed (NYSE: ... ) und 3B Medical ( Winter Haven, Florida ... eine Vereinbarung über die Beilegung aller globalen Rechtsstreitigkeiten zwischen ... der Verkauf ihrer bestehenden Produkte im Tausch gegen ... Zahlung an 3B leisten, um das in ...
(Date:1/22/2017)... Saudi Arabia , January 22, 2017 ... US and UAE discuss ... at the World Economic Forum   "The management and delivery ... data and powered by artificial intelligence and this trend is going to get ... of the Future, at the concluding day of the 47 th Annual ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... Zachary Cattell, President of ... a healthcare industry expert at the 2017 Sector Summit hosted by Ivy Tech ... Business host Gerry Dick, will feature an employer and an association representative from ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Old School Labs™, ... added Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team of brand ... a bodybuilder in 2012 and in less than a year was able to turn ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... online education programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in ... seafood-rich diet. These resources have been developed for use by nutrition educators ...
(Date:1/22/2017)... ... 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing a unique ... buyers at the January ECRM Trade Show in Hilton Head, SC. , Zifam Pinnacle ... in all of its creations to help create a more traditional and natural approach ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... "ProDOF is the perfect set of tools ... to another subject in a scene," said Christina Austin - CEO of Pixel Film Studios. ... scene. Easily create the illusion of a DSLR racking focus from one area into ...
Breaking Medicine News(10 mins):